Evidence map›Paper›PMID 26872334›Full record

ArticlePLoS neglected tropical diseases2016

Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.

Rebecca J Faleiro, Rajiv Kumar, Patrick T Bunn, Neetu Singh, Shashi Bhushan Chauhan, Meru Sheel, Fiona H Amante, Marcela Montes de Oca, Chelsea L Edwards, Susanna S Ng and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Emerging therapeutic targets for treatment of leishmaniasis.Expert opinion on therapeutic targets · 2018
    Review
  11. Article
  12. Analysis of the Antigenic and Prophylactic Properties of theFrontiers in cellular and infection microbiology · 2018
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 4 countries.

Rebecca J FaleiroQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Rajiv KumarQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Patrick T BunnQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Neetu SinghBanaras Hindu University Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.
Shashi Bhushan ChauhanBanaras Hindu University Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.
Meru SheelQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Fiona H AmanteQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Marcela Montes de OcaQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Chelsea L EdwardsQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Susanna S NgQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Shannon E BestQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Ashraful HaqueQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Lynette BeattieQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Louise M HafnerQueensland University of Technology, Institute of Health and Biomedical Innovation, Brisbane, Australia.
David SacksNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Susanne NylenKarolinska Institute, Stockholm, Sweden.
Shyam SundarBanaras Hindu University Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.
Christian R EngwerdaQIMR Berghofer Medical Research Institute, Brisbane, Australia.
QIMR Berghofer Medical Research Institute · AUInstitute of Medical Sciences · INQueensland University of Technology · AUBanaras Hindu University · INGriffith University · AUKarolinska Institutet · SENational Institutes of Health · USNetaji Subhas University of Technology · INUniversity of Queensland · AU

Funding

IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASISZIAAI000494 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SACKS, DAVID · 2009 to 2025
$11.8M
Visceral Leishmaniasis in Bihar State, IndiaP50AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2007 to 2016
$6.4M
Visceral Leishmaniasis in Bihar State, IndiaU19AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2017 to 2021
$2.8M
NIAID NIH HHS 2P50AI074321NIAID NIH HHS P50 AI074321NIAID NIH HHS U19 AI074321
6 · The paper itself

Abstract

Chronic disease caused by infections, cancer or autoimmunity can result in profound immune suppression. Immunoregulatory networks are established to prevent tissue damage caused by inflammation. Although these immune checkpoints preserve tissue function, they allow pathogens and tumors to persist, and even expand. Immune checkpoint blockade has recently been successfully employed to treat cancer. This strategy modulates immunoregulatory mechanisms to allow host immune cells to kill or control tumors. However, the utility of this approach for controlling established infections has not been extensively investigated. Here, we examined the potential of modulating glucocorticoid-induced TNF receptor-related protein (GITR) on T cells to improve anti-parasitic immunity in blood and spleen tissue from visceral leishmaniasis (VL) patients infected with Leishmania donovani. We found little effect on parasite growth or parasite-specific IFNγ production. However, this treatment reversed the improved anti-parasitic immunity achieved by IL-10 signaling blockade. Further investigations using an experimental VL model caused by infection of C57BL/6 mice with L. donovani revealed that this negative effect was prominent in the liver, dependent on parasite burden and associated with an accumulation of Th1 cells expressing high levels of KLRG-1. Nevertheless, combined anti-IL-10 and anti-GITR mAb treatment could improve anti-parasitic immunity when used with sub-optimal doses of anti-parasitic drug. However, additional studies with VL patient samples indicated that targeting GITR had no overall benefit over IL-10 signaling blockade alone at improving anti-parasitic immune responses, even with drug treatment cover. These findings identify several important factors that influence the effectiveness of immune modulation, including parasite burden, target tissue and the use of anti-parasitic drug. Critically, these results also highlight potential negative effects of combining different immune modulation strategies.

Indexed as

ImmunotherapyAnimalsCytokinesFemaleHumansInterleukin-10Leishmania donovaniLeishmaniasis, VisceralMiceMice, Inbred C57BLSpleenTh1 CellsCytokinesInterleukin-10

Identifiers

PMID26872334
PMCPMC4752322
OpenAlexW2268697566

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.